A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib

Objective: To mine the adverse drug event (ADE) signals of upadacitinib based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to provide a reference for the safe clinical use of the drug.Methods: The ADE data for upadacitinib from Q1 2004 to Q1 2023 in the F...

Full description

Bibliographic Details
Main Authors:	Yan Wu, Meihao Wei, Jing Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Pharmacology
Subjects:	adverse event FAERS database upadacitinib therapeutic drug monitoring pharmacovigilance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1200254/full

Similar Items

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
by: Wei Chen, et al.
Published: (2024-02-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023-12-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
by: Tingting Jiang, et al.
Published: (2022-12-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-07-01)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022-11-01)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
by: Qilin Zhang, et al.
Published: (2023-08-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database
by: Xiayang Ren, et al.
Published: (2024-01-01)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
by: Shu Tang, et al.
Published: (2022-10-01)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023-01-01)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024-01-01)

Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
by: SHE Youjun, GUO Zihan, ZHANG Zhongwei, DU Qiong
Published: (2023-10-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024-03-01)

Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021
by: YanFeng Wang, et al.
Published: (2022-10-01)

Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
by: Jingrui Zou, et al.
Published: (2022-11-01)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023-04-01)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
by: Shu Y, et al.
Published: (2022-06-01)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseResearch in context
by: Chaozheng Zhou, et al.
Published: (2023-05-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
by: Chanjuan Cui, et al.
Published: (2022-08-01)

Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)
by: Beatriz Marinho Silva Romão, et al.
Published: (2024-01-01)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
by: Linlin Tang, et al.
Published: (2024-02-01)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
by: Xiujuan Gui, et al.
Published: (2023-10-01)